CYAD

COM:CELYAD

Celyad Oncology

Add to Watchlist
  • Stock

0.46

+0.22%

0.00

EUR last updated 25/07 01:50:18

Last Close

0.46

02/05 08:16

Market Cap

11.14M

Beta: -

Volume Today

1.30K

Avg: -

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA ...Show More